These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19070809)

  • 61. A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma.
    Beckermann KE; Rini BI
    Nat Rev Clin Oncol; 2023 Sep; 20(9):581-582. PubMed ID: 37353556
    [No Abstract]   [Full Text] [Related]  

  • 62. Management of metastatic renal cell carcinoma: The complexity of choice.
    Brown JT; Bilen MA
    EBioMedicine; 2019 Sep; 47():2-3. PubMed ID: 31501075
    [No Abstract]   [Full Text] [Related]  

  • 63. [Syndromes of shock and adaptation to renal physiopathology in course of the hypertensive phase observed in therapeutic hypotension].
    JACQUET M
    Angeiol Ann Soc Fr Angeiol Histopathol; 1951 Oct; 58(18):33-5. PubMed ID: 14903602
    [No Abstract]   [Full Text] [Related]  

  • 64. What a Clinician Should Know About a Renal Replacement Membrane?
    Honore PM; Spapen HD
    J Transl Int Med; 2018 Jun; 6(2):62-65. PubMed ID: 29984198
    [No Abstract]   [Full Text] [Related]  

  • 65. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 66. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
    Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
    Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 68. Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.
    Figlin RA
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):662-5. PubMed ID: 20040906
    [No Abstract]   [Full Text] [Related]  

  • 69. [Management of toxicities due to anti-angiogenic treatment of metastatic renal carcinoma].
    Méjean A; Lebret T
    Prog Urol; 2008 Nov; 18 Suppl 7():S315-9. PubMed ID: 19070809
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeted molecular therapy for renal cell carcinoma.
    Lane BR; Rini BI; Novick AC; Campbell SC
    Urology; 2007 Jan; 69(1):3-10. PubMed ID: 17270598
    [No Abstract]   [Full Text] [Related]  

  • 72. [Critical analysis of prognostic factors for metastatic renal cell carcinoma].
    Neuzillet Y; Coulange C
    Prog Urol; 2009 Jun; 19(6):383-8. PubMed ID: 19467456
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.